José M Ferro1,2,3, Martin Bendszus4, Olav Jansen5, Jonathan M Coutinho6, Francesco Dentali7, Adam Kobayashi8, Diana Aguiar de Sousa1,2,3, Lia L Neto3,9, Corinna Miede10, Jorge Caria11, Holger Huisman12, Hans-Christoph Diener13. 1. Department of Neurosciences and Mental Health, Serviço de Neurologia, Hospital Santa Maria, Lisbon, Portugal. 2. Instituto de Medicina Molecular, Universidade de Lisboa, Lisboa, Portugal. 3. Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal. 4. Neurologische Klinik, Abteilung für Neuroradiologie, Universitätsklinikum Heidelberg, Heidelberg, Germany. 5. Department of Radiology and Neuroradiology, University of Kiel, Kiel, Germany. 6. Department of Neurology, Amsterdam University Medical Centers, Amsterdam, the Netherlands. 7. Department of Medicine and Surgery, Insubria University, Varese, Italy. 8. Faculty of Health Sciences and Physical Education, Kazimierz Pulaski University of Technology and Humanities, Radom, Poland. 9. Serviço de Neuroradiologia, Hospital Santa Maria/Centro Hospitalar Lisboa Norte, Lisboa, Portugal. 10. HMS Analytical Software GmbH, Weimar (Lahn), Germany. 11. Boehringer Ingelheim International, Ingelheim am Rhein, Germany. 12. Boehringer Ingelheim B.V., Alkmaar, the Netherlands. 13. Faculty of Medicine, University Duisburg-Essen, Essen, Germany.
Abstract
BACKGROUND: The effect of different anticoagulants on recanalization after cerebral venous thrombosis has not been studied in a randomized controlled trial. METHODS: RE-SPECT CVT (ClinicalTrials.gov number: NCT02913326) was a Phase III, prospective, randomized, parallel-group, open-label, multicenter, exploratory trial with blinded endpoint adjudication. Acute cerebral venous thrombosis patients were allocated to dabigatran 150 mg twice daily, or dose-adjusted warfarin, for 24 weeks, after 5-15 days' treatment with unfractionated or low-molecular-weight heparin. A standardized magnetic resonance protocol including arterial spin labeling, three-dimensional time-of-flight venography, and three-dimensional contrast-enhanced magnetic resonance angiography was obtained at the end of the treatment period. Cerebral venous recanalization at six months was assessed by two blinded adjudicators, using the difference in a score of occluded sinuses and veins (predefined secondary efficacy endpoint) and in the modified Qureshi scale (additional endpoint), between baseline and the end of the treatment. RESULTS: Of 120 cerebral venous thrombosis patients randomized, venous recanalization could be evaluated in 108 (55 allocated to dabigatran and 53 to warfarin, 1 patient had a missing occlusion score at baseline). No patient worsened in the score of occluded cerebral veins and sinuses, while 33 (60%) on dabigatran and 35 (67%) on warfarin improved. The mean score change from baseline in the occlusion score was similar in the two treatment groups (dabigatran -0.8, SD 0.78; warfarin -1.0, SD 0.92). In the modified Qureshi score, full recanalization was adjudicated in 24 (44%) and 19 (36%), and partial recanalization in 23 (42%) and 26 (49%) patients in the dabigatran and warfarin arms, respectively. No statistically significant treatment difference in the modified Qureshi score could be detected (p = 0.44). CONCLUSION: The majority of patients with cerebral venous thrombosis, anticoagulated with either dabigatran or warfarin for six months, showed partial or complete recanalization of occluded sinuses and veins at the end of the treatment.Clinical trial registration: Trial registry name: ClinicalTrials.gov URL: https://clinicaltrials.gov Registration number: NCT02913326.
BACKGROUND: The effect of different anticoagulants on recanalization after cerebral venous thrombosis has not been studied in a randomized controlled trial. METHODS: RE-SPECT CVT (ClinicalTrials.gov number: NCT02913326) was a Phase III, prospective, randomized, parallel-group, open-label, multicenter, exploratory trial with blinded endpoint adjudication. Acute cerebral venous thrombosis patients were allocated to dabigatran 150 mg twice daily, or dose-adjusted warfarin, for 24 weeks, after 5-15 days' treatment with unfractionated or low-molecular-weight heparin. A standardized magnetic resonance protocol including arterial spin labeling, three-dimensional time-of-flight venography, and three-dimensional contrast-enhanced magnetic resonance angiography was obtained at the end of the treatment period. Cerebral venous recanalization at six months was assessed by two blinded adjudicators, using the difference in a score of occluded sinuses and veins (predefined secondary efficacy endpoint) and in the modified Qureshi scale (additional endpoint), between baseline and the end of the treatment. RESULTS: Of 120 cerebral venous thrombosis patients randomized, venous recanalization could be evaluated in 108 (55 allocated to dabigatran and 53 to warfarin, 1 patient had a missing occlusion score at baseline). No patient worsened in the score of occluded cerebral veins and sinuses, while 33 (60%) on dabigatran and 35 (67%) on warfarin improved. The mean score change from baseline in the occlusion score was similar in the two treatment groups (dabigatran -0.8, SD 0.78; warfarin -1.0, SD 0.92). In the modified Qureshi score, full recanalization was adjudicated in 24 (44%) and 19 (36%), and partial recanalization in 23 (42%) and 26 (49%) patients in the dabigatran and warfarin arms, respectively. No statistically significant treatment difference in the modified Qureshi score could be detected (p = 0.44). CONCLUSION: The majority of patients with cerebral venous thrombosis, anticoagulated with either dabigatran or warfarin for six months, showed partial or complete recanalization of occluded sinuses and veins at the end of the treatment.Clinical trial registration: Trial registry name: ClinicalTrials.gov URL: https://clinicaltrials.gov Registration number: NCT02913326.
Authors: A Hakim; C Kurmann; K Pospieszny; T R Meinel; M A Shahin; M R Heldner; R Umarova; S Jung; M Arnold; M El-Koussy Journal: AJNR Am J Neuroradiol Date: 2022-05-26 Impact factor: 4.966
Authors: Christina Geisbüsch; Christian Herweh; Christoph Gumbinger; Peter A Ringleb; Markus A Möhlenbruch; Simon Nagel Journal: Neurol Res Pract Date: 2021-05-17
Authors: Lukas Kellermair; Matthias W G Zeller; Caterina Kulyk; Josef Tomasits; Tim J von Oertzen; Milan R Vosko Journal: Life (Basel) Date: 2022-06-28
Authors: Anita van de Munckhof; Erik Lindgren; Timothy J Kleinig; Thalia S Field; Charlotte Cordonnier; Katarzyna Krzywicka; Sven Poli; Mayte Sánchez van Kammen; Afshin Borhani-Haghighi; Robin Lemmens; Adrian Scutelnic; Alfonso Ciccone; Thomas Gattringer; Matthias Wittstock; Vanessa Dizonno; Annemie Devroye; Ahmed Elkady; Albrecht Günther; Alvaro Cervera; Annerose Mengel; Beng Lim Alvin Chew; Brian Buck; Carla Zanferrari; Carlos Garcia-Esperon; Christian Jacobi; Cristina Soriano; Dominik Michalski; Zohreh Zamani; Dylan Blacquiere; Elias Johansson; Elisa Cuadrado-Godia; Fabrice Vuillier; Felix J Bode; François Caparros; Frank Maier; Georgios Tsivgoulis; Hans D Katzberg; Jiangang Duan; Jim Burrow; Johann Pelz; Joshua Mbroh; Joyce Oen; Judith Schouten; Julian Zimmermann; Karl Ng; Katia Garambois; Marco Petruzzellis; Mariana Carvalho Dias; Masoud Ghiasian; Michele Romoli; Miguel Miranda; Miriam Wronski; Mona Skjelland; Mostafa Almasi-Dooghaee; Pauline Cuisenier; Seán Murphy; Serge Timsit; Shelagh B Coutts; Silvia Schönenberger; Simon Nagel; Sini Hiltunen; Sophie Chatterton; Thomas Cox; Thorsten Bartsch; Vahid Shaygannejad; Zahra Mirzaasgari; Saskia Middeldorp; Marcel M Levi; Johanna A Kremer Hovinga; Katarina Jood; Turgut Tatlisumak; Jukka Putaala; Mirjam R Heldner; Marcel Arnold; Diana Aguiar de Sousa; José M Ferro; Jonathan M Coutinho Journal: Stroke Date: 2022-09-09 Impact factor: 10.170